Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jun;33(6):906–914. doi: 10.1128/aac.33.6.906

In vitro and in vivo antibacterial activities of BMY 40062, a new fluoronaphthyridone.

J Fung-Tomc 1, J V Desiderio 1, Y H Tsai 1, G Warr 1, R E Kessler 1
PMCID: PMC284253  PMID: 2764541

Abstract

The in vitro and in vivo activities of a new naphthyridone, BMY 40062, were compared with those of ciprofloxacin and ofloxacin. BMY 40062 showed about threefold more activity than ciprofloxacin showed and four- to eightfold more activity than ofloxacin showed against staphylococci, streptococci, and enterococci. BMY 40062 showed generally twofold less activity than ciprofloxacin showed against most species of the family Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. but twofold more activity than ofloxacin showed against these organisms. BMY 40062 and ofloxacin were more active than ciprofloxacin against Bacteroides fragilis and Clostridium difficile. The antiureaplasmal and antichlamydial activities of BMY 40062 were similar to those of the tetracyclines and were 4- and 16-fold, respectively, higher than those of ciprofloxacin. The in vitro activities of BMY 40062 were influenced by pH and magnesium, although these factors appeared to affect the activity of BMY 40062 against P. aeruginosa to a lesser extent than those of ciprofloxacin and ofloxacin. BMY 40062 was found to be bactericidal, and cross-resistance with other fluoroquinolones was observed. In mouse protection tests, the efficacy of BMY 40062 reflected its in vitro potency. BMY 40062 exhibited longer half-life, higher maximum concentration in serum, greater area under the curve, and better bioavailability in mice after oral dosing than ciprofloxacin. Compared with ofloxacin, BMY 40062 had a lower maximum concentration in serum but a much longer half-life in mice. BMY 40062 was more effective than ciprofloxacin and ofloxacin in penetrating mouse macrophages and killing macrophage-associated Staphylococcus aureus.

Full text

PDF
906

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chapman J. S., Georgopapadakou N. H. Routes of quinolone permeation in Escherichia coli. Antimicrob Agents Chemother. 1988 Apr;32(4):438–442. doi: 10.1128/aac.32.4.438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chin N. X., Novelli A., Neu H. C. In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones. Antimicrob Agents Chemother. 1988 May;32(5):656–662. doi: 10.1128/aac.32.5.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Davies B. I., Maesen F. P., Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol. 1986 Apr;5(2):226–231. doi: 10.1007/BF02013995. [DOI] [PubMed] [Google Scholar]
  4. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kessler R. E., Bies M., Buck R. E., Chisholm D. R., Pursiano T. A., Tsai Y. H., Misiek M., Price K. E., Leitner F. Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics. Antimicrob Agents Chemother. 1985 Feb;27(2):207–216. doi: 10.1128/aac.27.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Leland D. S., Lapworth M. A., Jones R. B., French M. L. Comparative evaluation of media for isolation of ureaplasma urealyticum and genital mycoplasma species. J Clin Microbiol. 1982 Oct;16(4):709–714. doi: 10.1128/jcm.16.4.709-714.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ridgway G. L. Antimicrobial chemotherapy of chlamydial infection: where next? Eur J Clin Microbiol. 1986 Oct;5(5):550–553. doi: 10.1007/BF02017703. [DOI] [PubMed] [Google Scholar]
  8. Righter J. Ciprofloxacin treatment of Staphylococcus aureus infections. J Antimicrob Chemother. 1987 Oct;20(4):595–597. doi: 10.1093/jac/20.4.595. [DOI] [PubMed] [Google Scholar]
  9. Saito A., Sawatari K., Fukuda Y., Nagasawa M., Koga H., Tomonaga A., Nakazato H., Fujita K., Shigeno Y., Suzuyama Y. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother. 1985 Jul;28(1):15–20. doi: 10.1128/aac.28.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sanders C. C., Sanders W. E., Jr, Goering R. V. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed] [Google Scholar]
  11. Smith J. T., Ratcliffe N. T. Einfluss von pH-Wert und Magnesium auf die antibakterielle Aktivität von Chinolonpräparaten. Infection. 1986;14 (Suppl 1):S31–S35. doi: 10.1007/BF01645195. [DOI] [PubMed] [Google Scholar]
  12. Walker R. C., Wright A. J. Symposium on antimicrobial agents. The quinolones. Mayo Clin Proc. 1987 Nov;62(11):1007–1012. doi: 10.1016/s0025-6196(12)65073-3. [DOI] [PubMed] [Google Scholar]
  13. Wilkins T. D., Chalgren S. Medium for use in antibiotic susceptibility testing of anaerobic bacteria. Antimicrob Agents Chemother. 1976 Dec;10(6):926–928. doi: 10.1128/aac.10.6.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zervos M. J., Bacon A. E., 3rd, Patterson J. E., Schaberg D. R., Kauffman C. A. Enterococcal superinfection in patients treated with ciprofloxacin. J Antimicrob Chemother. 1988 Jan;21(1):113–115. doi: 10.1093/jac/21.1.113. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES